Berberine prevents NAFLD and HCC by modulating metabolic disorders

Pharmacol Ther. 2024 Feb:254:108593. doi: 10.1016/j.pharmthera.2024.108593. Epub 2024 Feb 1.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a global metabolic disease with high prevalence in both adults and children. Importantly, NAFLD is becoming the main cause of hepatocellular carcinoma (HCC). Berberine (BBR), a naturally occurring plant component, has been demonstrated to have advantageous effects on a number of metabolic pathways as well as the ability to kill liver tumor cells by causing cell death and other routes. This permits us to speculate and make assumptions about the value of BBR in the prevention and defense against NAFLD and HCC by a global modulation of metabolic disorders. Herein, we briefly describe the etiology of NAFLD and NAFLD-related HCC, with a particular emphasis on analyzing the potential mechanisms of BBR in the treatment of NAFLD from aspects including increasing insulin sensitivity, controlling the intestinal milieu, and controlling lipid metabolism. We also elucidate the mechanism of BBR in the treatment of HCC. More significantly, we provided a list of clinical studies for BBR in NAFLD. Taking into account our conclusions and perspectives, we can make further progress in the treatment of BBR in NAFLD and NAFLD-related HCC.

Keywords: Berberine; Hepatocellular carcinoma (HCC); Metabolic disorders (MetS); Non-alcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH).

Publication types

  • Review

MeSH terms

  • Berberine* / pharmacology
  • Berberine* / therapeutic use
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / prevention & control
  • Child
  • Humans
  • Insulin Resistance*
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / prevention & control
  • Non-alcoholic Fatty Liver Disease* / drug therapy
  • Non-alcoholic Fatty Liver Disease* / metabolism

Substances

  • Berberine